News & Updates
Filter by Specialty:
Long-term aspirin use lowers HCC risk in chronic HBV patients
Use of aspirin in the long term appears to markedly reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV), a study has shown.
Long-term aspirin use lowers HCC risk in chronic HBV patients
14 May 2022Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
Administration of oral silymarin leads to a substantial decrease in hepatotoxicity severity after 1 month of treatment in nonmetastatic breast cancer patients on doxorubicin/cyclophosphamide-paclitaxel (AC-T) regimen, reports a study.
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
06 May 2022Seladelpar safe, effective for primary biliary cholangitis
In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.
Seladelpar safe, effective for primary biliary cholangitis
10 Apr 2022Hepatitis B virus treatment rates still low among eligible patients
Administration rates of antiviral therapy remain low among treatment-eligible patients with chronic hepatitis B virus (CHB) and among CHB patients without human immunodeficiency virus (HIV), reveals a recent study.
Hepatitis B virus treatment rates still low among eligible patients
10 Apr 2022Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
27 Mar 2022Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
Extracellular vesicles enriched with the polymeric immunoglobulin receptor molecule contributes to tumorigenesis and cancer stemness in patients with hepatocellular carcinoma (HCC), reports a recent study.
Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
26 Mar 2022Respiratory-gated PET-CT improves liver tumour imaging
A prospective clinical study conducted by the Hong Kong Baptist Hospital in collaboration with the Hong Kong Polytechnic University has demonstrated the feasibility of implementing respiratory-gated PET-CT for liver malignancies with improved image quality compared with ungated scans.
Respiratory-gated PET-CT improves liver tumour imaging
17 Mar 2022Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.